ADVERTISEMENT
Lupin Banks On Key Products For U.S. Growth Revival
Lupin’s Nilesh Gupta on the U.S. market, drug approvals, capacity addition and more...
19 Sep 2019, 12:43 PM IST
Shares of Lupin Ltd. have declined by nearly a quarter in the last two years compared with the Nifty Pharma Index’s 15 percent decline. India’s fifth-largest generic drugmaker faces intense competition and pricing pressure in the U.S., its largest market.Its problems don’t end there. Four of Lupin’s plants are under the U.S. Food and Drug Administration’s scanner, raising questions over future product pipelines. The company’s plant a...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT